Genspera, Inc. Appoints Dr. Peter E. Grebow to its Board of Directors
May 31, 2012 at 08:02 am
Share
Genspera, Inc. announced the appointment of Peter E. Grebow, Ph.D. to its Board of Directors. Dr. Grebow will be the company's third independent director and will serve on the company's (i) Audit Committee, (ii) Nominating and Corporate Governance Committee, and (iii) Leadership Development and Compensation Committee, of which he will chair the Nomination and Corporate Governance Committee. With the appointment of Dr. Grebow to the board and committees, GenSpera now meets NASDAQ's corporate governance requirements regarding director independence and committee composition. Dr. Grebow, age 65, has had a 37-year career in the pharmaceutical industry. From 1991 to 2011, he held several key positions with Cephalon, Inc. (now Teva Pharmaceuticals), most significantly, Senior Vice President Drug Development, Senior Vice president Business Development and Executive Vice President of Technical Operations.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
